[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

After the FDA adopted a more positive stance towards uniQure's (QURE) gene therapy for Huntington's Disease, AMT-130, the agency is likely to approve the biologic treatment. As a result, QURE stock is dramatically undervalued compared with its long-term potential. However, it still poses a significant risk, making it a buy for long-term growth investors with a meaningful tolerance for risk.

On June 17, uniQure reported that, during a meeting with the FDA, the agency had stated that the results of a Phase I/II study of AMT-130 “would be acceptable as the primary basis” for an application for “accelerated approval” of...

Fundamentals

See More
  • Market Capitalization, $K 2,919,325
  • Shares Outstanding, K 63,066
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -198,970 K
  • EBIT $ -192 M
  • EBITDA $ -177 M
  • 60-Month Beta 0.98
  • Price/Sales 188.67
  • Price/Cash Flow N/A
  • Price/Book 20.16

Options Overview Details

View History
  • Implied Volatility 100.69% (+0.33%)
  • Historical Volatility 183.32%
  • IV Percentile 29%
  • IV Rank 12.00%
  • IV High 302.43% on 02/17/26
  • IV Low 73.19% on 10/03/25
  • Expected Move (DTE 27) 9.10 (19.65%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 42,137
  • Volume Avg (30-Day) 8,031
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 161,394
  • Open Int (30-Day) 134,625
  • Expected Range 37.20 to 55.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.88
  • Number of Estimates 4
  • High Estimate $-0.82
  • Low Estimate $-1.05
  • Prior Year $-0.69
  • Growth Rate Est. (year over year) -27.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.00 +92.88%
on 05/26/26
50.08 -7.57%
on 06/18/26
+21.36 (+85.68%)
since 05/18/26
3-Month
13.21 +250.42%
on 04/10/26
50.08 -7.57%
on 06/18/26
+31.56 (+214.26%)
since 03/18/26
52-Week
8.73 +430.24%
on 03/03/26
71.50 -35.26%
on 10/28/25
+31.19 (+206.56%)
since 06/18/25

Most Recent Stories

More News
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026...

QURE : 46.29 (-3.88%)
uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

uniQure stock looks poised to soar over the long term, but it does pose meaningful risk.

QURE : 46.29 (-3.88%)
Stocks Retreat as Fed Signals Possible Higher Interest Rates

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.98%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.99%. June...

GOOGL : 368.03 (+1.17%)
AAPL : 298.01 (+0.70%)
FDXF : 162.85 (+0.59%)
TSLA : 400.49 (+1.04%)
AMD : 537.37 (+4.86%)
CME : 246.38 (-2.44%)
SPY : 746.74 (+1.04%)
META : 577.22 (+1.70%)
ADSK : 193.82 (+0.39%)
MU : 1,133.99 (+8.70%)
ORCL : 184.29 (+0.41%)
QQQ : 740.62 (+2.51%)
Stocks Mixed Ahead of FOMC Meeting Results

The S&P 500 Index ($SPX ) (SPY ) today is down -0.15%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.30%. June E-mini S&P futures (ESM26...

GOOGL : 368.03 (+1.17%)
AAPL : 298.01 (+0.70%)
ADI : 434.46 (+4.83%)
FDXF : 162.85 (+0.59%)
TSLA : 400.49 (+1.04%)
JBL : 371.88 (-0.83%)
AMD : 537.37 (+4.86%)
CME : 246.38 (-2.44%)
SPY : 746.74 (+1.04%)
META : 577.22 (+1.70%)
MU : 1,133.99 (+8.70%)
QQQ : 740.62 (+2.51%)
Stocks Supported by Chip Stock Strength and Strong US Retail Sales

The S&P 500 Index ($SPX ) (SPY ) today is up +0.23%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.74%. June E-mini S&P futures (ESM26...

AMAT : 617.11 (+4.08%)
AVGO : 411.35 (+4.70%)
VZ : 45.37 (-1.03%)
REXR : 33.12 (+2.00%)
$IUXX : 30,406.19 (unch)
WNC : 11.36 (+5.19%)
ASML : 1,929.68 (+3.31%)
ZNU26 : 109-105 (-0.27%)
ESU26 : 7,556.25s (-0.19%)
T : 22.01 (-1.92%)
QCOM : 226.11 (+6.17%)
JBL : 371.88 (-0.83%)
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter...

QURE : 46.29 (-3.88%)
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 46.29 (-3.88%)
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on...

QURE : 46.29 (-3.88%)
uniQure Reports Tuesday With Regulatory Hope Intact but Financial Runway Shrinking Fast

Barchart Research What to Expect from QURE Earnings QURE Generated May 4, 2026 Current Price $20.68 EPS Estimate $$-0.88 Consensus Rating Moderate Buy Average Move 8.91% uniQure Reports Tuesday With Regulatory...

QURE : 46.29 (-3.88%)
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected  in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential...

QURE : 46.29 (-3.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed below 80%. The market has dropped from extreme overbought territory, indicating a possible trend reversal.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 53.31
2nd Resistance Point 51.70
1st Resistance Point 48.99
Last Price 46.29
1st Support Level 44.67
2nd Support Level 43.06
3rd Support Level 40.35

See More

52-Week High 71.50
Fibonacci 61.8% 47.52
Last Price 46.29
Fibonacci 50% 40.11
Fibonacci 38.2% 32.71
52-Week Low 8.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.